Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
In this phase II trial, we will evaluate the feasibility and efficacy of the
oxaliplatin/capecitabine combination in patients who have had one previous chemotherapy
regimen for the treatment of carcinoma of unknown primary site. Patients who are relapsed
after a previous response to treatment will be eligible, as well as those who were refractory
to first-line therapy.